Live Updates: U.S. recommends “pause” for Johnson & Johnson COVID vaccine to review blood clot cases – CBS News

The Centers for Disease Control indicated in an alert Tuesday that the Johnson & & Johnson vaccine could resume as quickly as Wednesday. The alert came after a chaotic day when the Food and Drug Administration advised there be a “pause” for the vaccine, leading essentially every state to stop usage of the single-dose shot.
The CDCs Advisory Committee on Immunization Practices will assemble Wednesday for an emergency situation session, with a vote scheduled on “upgraded recommendations for use” before the group adjourns at 4:30 p.m. ET.
Dr. Anthony Fauci, President Bidens primary medical consultant, informed “CBS Evening News” anchor Norah ODonnell on Tuesday night that it appeared that the adverse result occurred within 6 to 13 days, and “so if youve had it a month or two back, I think you truly do not need to stress over anything.”
Fauci emphasized that the chance of these negative adverse effects is “less than 1 in a million,” but he said to be alert to the signs such as severe headache, some difficulty in motion– such as in a neurological type of a circumstance– or some chest pain and problem breathing.
Since Monday, more than 6.8 million dosages of the Johnson & & Johnson vaccine had actually been administered throughout the U.S., a small part of the overall 190 million COVID vaccine shots given nationwide– most of them from Pfizer and Moderna.
The White House stated Tuesday that the pause “will not have a considerable impact” on the nationwide vaccine plan. President Biden guaranteed Americans that he had made certain the U.S. has enough vaccine doses for all American grownups from Pfizer and Moderna alone..
The handful of cases the FDA and CDC are examining occurred in females and included an embolism called cerebral venous sinus thrombosis, which was seen along with low levels of blood platelets, according to their declaration. Signs were seen 6 to 13 days after vaccination in the ladies, who were between the ages of 18 and 48.
” Treatment of this particular kind of blood embolism is various from the treatment that might generally be administered. Normally, an anticoagulant drug called heparin is utilized to treat embolism. In this setting, administration of heparin may be unsafe, and alternative treatments require to be offered,” they stated.
The companies said the “unfavorable events” seem to be extremely rare, however that the pause is essential so that health care service providers can be made aware of the reactions and correctly recognize and handle the cases, provided the unique treatment needed.
Ed OKeefe contributed to this report.

Leave a Reply

Your email address will not be published. Required fields are marked *